Compare JPMorgan Chase & Co (JPM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Moderna, Inc. — how do they compare? JPMorgan Chase & Co trades at $333.39 (market cap $880.98B), while Moderna, Inc. trades at $224.78 (market cap $78.65B). The key difference: JPMorgan Chase & Co is far larger — about 11.2× Moderna, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Moderna, Inc. for 59 Days on average.
| JPM | MRNA | |
|---|---|---|
Market Cap | $880.98B | $78.65B |
Volume | 7,721,661 | 37,373,437 |
Sector | Financials | Health |
52-Week High | $365.18 | $203.46 |
52-Week Low | $282.84 | $22.36 |
Typical Hold Time | 127 Days | 59 Days |
Enterprise Value | $1.82T | $74.80B |
Dividend Yield | 1.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $332.99, up 1.03% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to a projected $194.9B in 2026. The stock shows a P/E of 14.2 and ROE of 18.43%, supported by a 'Moderate Buy' analyst consensus and a $373.18 price target. News highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
Outlook: JPM offers value with solid profitability and analyst upside, but risks include geopolitical tensions and cybersecurity threats. The stock's bearish technicals near support at $327 suggest caution, though institutional buying and high ROE provide stability. Investors should weigh strong fundamentals against macroeconomic headwinds highlighted in recent news.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
